News

Review abstracts, posters, oral comunications, plenary sessions and invited lectures related to our research programs, lab services, partner collaborations and other topics related to our science

2024

Immune Checkpoint Inhibitors Potency Assay using in vitro Expanded TILs

SITC 2024
2024 November
Houston, TX
Poster Presentation

Unlocking Clinical Potential for ADCs Through Improved Ex Vivo Assays

15th Annual World ADC Conference
2024 November
San Diego, CA
Poster Presentation

Optimizing Ex Vivo Assays: The Crucial Step for Advancing ADCs to Clinical Success

36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2024 October
Barcelona, Spain
Poster Presentation

Advancing Insights into Monoclonal Antibody Mechanisms: A Novel Ex Vivo Assay Using Whole Bone Marrow Environment to Investigate the Efficacy of Daratumumab in Multiple Myeloma

CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2024 June
Madrid, Spain
Poster Presentation

Activity of VIP943 on AML Patient-Derived Leukemic Blasts and Healthy Donor-Derived Bone Marrow Hematopoietic Stem Cells

AACR Annual Congress
2024 April
San Diego, CA (USA)
Poster Presentation

2023

Debio 1562M, a Next Generation Antibody Drug Conjugate (ADC) Targeting CD37 for AML and MDS Treatment

65th ASH Annual Meeting & Exposition
2023 December
San Diego, CA (USA)
Poster Presentation

WU-NK-101, A Best-in-Class Memory NK cell, Has Key Features Vital for Adoptive Cell Therapy (ACT) in Solid Tumors (ST)

ESMO Congress
2023 October
Madrid, Spain
Poster Presentation

WU-NK-101, an Enhanced Memory Natural Killer (NK) Cell Therapy, with Cetuximab (Ctx) for the Treatment of Advanced Colorectal Cancer (CRC)

ASCO Gastrointestinal Cancers Symposium
2023 January
San Francisco, CA (USA)
Poster Presentation

2022

VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models

64th ASH Annual Meeting & Exposition 2022 December
New Orleans, LA (USA)
Poster presentation

Putative Predictors of Response to WU-NK-101, an Allogenic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia

64th ASH Annual Meeting & Exposition
2022 December
New Orleans, LA (USA)
Poster presentation

Preclinical Characterization of NGM936, a Novel Bispecific T Cell Engager Targeting ILT3 for the Treatment of Acute Myeloid Leukemia with Monocytic Differentiation

64th ASH Annual Meeting & Exposition
2022 December
New Orleans, LA (USA)
Poster presentation

WU-NK-101: an Enhanced NK Cell Therapy Optimized for Function in the Tumor Microenvironment (TME)

ESMO Congress
2022 September
Paris, France
Poster Presentation

Improving NK Cell Function in Multiple Myeloma with NKTR-225, a Novel Polymer-Conjugated Human IL-15

27th CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2022 June
Vienna, Austria (In person & Virtual)

WU-NK-101, an Allogenic Memory NK Cell, for the Treatment of Relapse or Refractory (R/R) Acute Myeloid Leukemia (AML)

27th CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2022 June
Vienna, Austria (In person & Virtual)

Bispecific Antibodies Activate Autologous Leukemia-Reactive T Cells in Acute Myeloid Leukemia

27th CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2022 June
Vienna, Austria (In person & Virtual)

2021

Avidity-Engineered CD3 Engaging DARPin Targeting Three Tumor Associated Antigens Induces Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety

63rd ASH Annual Meeting & Exposition
2021 December
Atlanta, GA, USA (In person & Virtual Congress)
Poster presentation

2020

Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients

62nd ASH Annual Meeting & Exposition
2020 December
Virtual Congress
Poster Presentation

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

62nd ASH Annual Meeting & Exposition
2020 December
Virtual Congress
Poster Presentation

Expanded and activated TILs kill tumor cells enabling IO compound assays

35th Anniversary Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2020)
2020 November
Virtual Congress
Poster Presentation

Bispecific T-cell engager antibodies may contribute to reactivate pre-existing Tumor specific T-Cells

25th CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2020 June
Virtual Congress
Poster Presentation

2019

NKG2D Chimeric Antigen Receptor-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells

61st ASH ANNUAL MEETING
2019 December
Orlando, FL, USA
Poster Presentation

Mutational Profile by NGS Combined with Ex Vivo Drug Sensitivity Profile Improve Prediction of AML Patient OutcomeNKG2D Chimeric Antigen Receptor-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells

24th CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2019 June
Amsterdam, The Netherlands
Poster presentation

Immuno-Oncology Functional Precision Medicine Assays by Trogocytosis

FUNCTIONAL PRECISION MEDICINE SUMMIT (AS PART OF AACR ANNUAL MEETING)
2019 April
Atlanta, USA
Poster presentation

In Vitro Characterization of TP-2846: A Novel Tetracycline Antileukemia Agent

AACR ANNUAL MEETING
2019 April
Atlanta, USA
Poster presentation

2018

Precision Medicine Test is Similar but Faster than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

60TH ASH ANNUAL MEETING
2018 December
San Diego, USA
Poster presentation

A New Mechanism for Bispecific T-Cell Engagers Reactivating Tumor-Selective T Cells in Acute Leukemia

BULGARIAN CONGRESS OF CLINICAL IMMUNOLOGY
2018 October
Plovdiv, Bulgaria
Invited Lecture

Estudio del Perfil Mutacional y Correlacion de Respuesta a Test Farmacológico Ex Vivo en el Diagnóstico de la LMA

LX CONGRESO NACIONAL SEHH
2018 October
Granada, Spain
Plenary Session

Evaluation of the Activity of IMiDS in MM Proliferating Cells

23RD CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2018 June
Stockholm, Sweden
Poster presentation

2017

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

59TH ASH ANNUAL MEETING
2017 December
Atlanta, USA
Poster presentation

Bispecific antibodies on hematological malignancies: a novel mechanism of action that may contribute to therapeutic efficacy

59TH ASH ANNUAL MEETING
2017 December
Atlanta, USA
Poster presentation

Nuevo Modelo para Cuantificar la Actividad Farmacológica In Vitro de Anticuerpos Biespecíficos en Hemopatías Malignas

LIX CONGRESO NACIONAL SEHH
2017 October
Málaga, Spain
Oral comunication

Ensayo Clínico Observacional para la Validación de un Test de Medicina de Precisión en Leucemia Mieloide Aguda

LIX CONGRESO NACIONAL SEHH
2017 October
Málaga, Spain
Oral comunication

Mode of Cytotoxic Action of T-Cell Bispecific Antibodies on Hematological Malignancies: a Novel In Vitro Approach

ESH 4TH INTERNATIONAL CONFERENCE ON ACUTE MYELOID LEUKEMIA “MOLECULAR AND TRANSLATIONAL”: ADVANCES IN BIOLOGY AND TREATMENT
2017 October
Estoril, Portugal
Poster presentation

A New Mechanism of Action for Bispecific Antibodies Activating Tumor-Specific Antigen T Cells

8TH ANNUAL WORLD BISPECIFIC SUMMIT
2017 September
Boston, MA
Conference speaker

A Novel Method to Capture the Pharmacological Activity of Bispecific Antibodies in Patients with Hematological Malignancies

THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE. TRANSLATING SCIENCE INTO SURVIVAL
2017 September
Mainz, Frankfurt
Poster presentation

Validation of Precision Medicine Test for Acute Myeloid Leukemia in an Observational Clinical Trial

22ND CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2017 June
Madrid, Spain
Poster presentation

A Novel In Vitro Method to Quantify the Pharmacology Activity of Bispecific Antibodies in Hematological Samples

22ND CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2017 June
Madrid, Spain
Poster presentation

A New Precision Medicine Test to Guide Personalized Treatments Decision for Acute Myeloid Leukemia Patients

AACR HEMATOLOGIC MALIGNANCIES: TRANSLATING DISCOVERIES TO NOVEL THERAPIES
2017 May
Boston, MA
Poster presentation

Pharmacological Evaluation of Bispecific Antibodies: A Novel Method to Quantify their In Vitro Activity in Hematological Samples

AACR HEMATOLOGIC MALIGNANCIES: TRANSLATING DISCOVERIES TO NOVEL THERAPIES
2017 May
Boston, MA
Poster presentation

2016

Ex Vivo Activity Profile of the CD123xCD3 DuoBody® antibody JNJ-63709178 against Primary Acute Myeloid Leukemia Bone Marrow Samples

58TH ASH ANNUAL MEETING
2016 December
San Diego, CA
Poster presentation

An Ex Vivo Native Environment Precision Medicine Test Shows High Clinical Correlation with Responses to First Line Acute Myeloid Leukemia Treatment

5TH INTERNATIONAL CONFERENCE ON PREDICTIVE, PREVENTIVE AND PERSONALIZED MEDICINE & MOLECULAR DIAGNOSTICS
2016 December
Valencia, Spain
Conference speaker

A Novel Native Environment Method for Evaluating Immune-Oncology Compounds by Flow Cytometry

PHARMACEUTICAL FLOW CYTOMETRY & IMAGING
2016 November
Stevenage, UK
Poster presentation

Un Nuevo Test de Medicina Personalizada Ex Vivo Utilizando Microambiente Nativo Muestra una Alta Correlación Clínica con Respuestas a Primera Línea de Tratamiento en Leucemia Mielode Aguda

LVIII CONGRESO NACIONAL SEHH
2016 October
Santiago de Compostela, Spain
Poster presentation

Prediccion de Respuesta al Tratamiento en Leucemia Mieloide Aguda: Perfil Mutacional (NGS) y Test Farmacológico Ex Vivo

LVIII CONGRESO NACIONAL SEHH
2016 October
Santiago de Compostela, Spain
Oral comunication

Test Ex Vivo de Sensibilidad a Tratamientos en la Leucemia Mieloblastica Aguda

JORNADA DE ACTUALIZACIÓN EN EL TRATAMIENTO DE LA LEUCEMIA AGUDA
2016 September
Madrid, Spain
Oral comunication

A New Mechanism of Action for Bispecific Antibodies Activating Tumor- Specific Antigen T Cells

7TH ANNUAL WORLD BISPECIFIC SUMMIT
2016 August
Boston, MA
Conference speaker

ExVivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity for Idelalisib and Ibrutinib on CLL Cells

21ST CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2016 June
Copenhagen, Denmark
Poster presentation

An Ex Vivo Native Environment Precision Medicine Test Shows High Clinical Correlation with Responses to 1st Line Acute Myeloid Leukemia Treatment

21ST CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA)
2016 June
Copenhagen, Denmark
Poster presentation

An Ex Vivo Native Environment Precision Medicine Test Shows High Clinical Correlation with Responses to 1st Line Acute Myeloid Leukemia Treatment

7TH INTERNATIONAL HEMATOLOGIC MALIGNANCIES CONFERENCE: BRIDGING THE GAP 2016 (BTG2016)
2016 February
Guangzhou, China
Poster presentation

ExVivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity for Idelalisib and Ibrutinib on CLL Cells

7TH INTERNATIONAL HEMATOLOGIC MALIGNANCIES CONFERENCE: BRIDGING THE GAP 2016 (BTG2016)
2016 February
Guangzhou, China
Poster presentation

2015

High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

57TH ASH ANNUAL MEETING
2015 December
Orlando, FL
Poster presentation

A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (ExviTech)

57TH ASH ANNUAL MEETING
2015 December
Orlando, FL
Poster presentation

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

57TH ASH ANNUAL MEETING
2015 December
Orlando, FL
Poster presentation

Test de Medicina Personalizada por Farmacología Ex Vivo en Ambiente Nativo para Leucemia Mieloide Aguda

SEHH
2015 October
Valencia, Spain
Poster presentation

Precision Medicine in Native Environment

LABCYTE SYMPOSIUM, ADVANCING LIFE SCIENCES RESEARCH WITH ACOUSTIC LIQUID HANDLING
2015 October
Boston, MA
Invited Lecture

High Correlation between Clinical Responses to 1st Line AML Patients Treated with Cytarabine and Idarubicin and their Pharmacological Profiles in Patient Samples Measured by ExviTech

ESH, INTERNATIONAL CONFERENCE ON AML “MOLECULAR AND TRANSLATIONAL” ADVANCES IN THE BIOLOGY AND TREATMENT
2015 September
Budapest, Hungary
Poster presentation

Native Environment Precision Medicine of Bispecific Immunotherapy Antibodies

6TH ANNUAL WORLD BISPECIFIC SUMMIT
2015 August
Boston, MA
Poster presentation

2014

Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples

56TH ASH ANNUAL MEETING
2014 December
Atlanta, GA
Poster presentation

Development of a High-Throughput Screening Assay with Nurse-Like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells

56TH ASH ANNUAL MEETING
2014 December
Atlanta, GA
Poster presentation

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors as an Estimate of Hematotoxicity

56TH ASH ANNUAL MEETING
2014 December
Atlanta, GA
Poster presentation

High Correlation Between Clinical Responses to First Line AML Patients Treated with Cytarabine and Idarubicin and their Pharmacological Profiles in Patient Samples Measured by ExviTech

26TH EORTC-NCI-AACR
2014 November
Barcelona, Spain
Poster presentation

Hematotoxicity Potential of New Drug Candidates Measured in Hematopoietic Progenitors in Bone Marrow Samples

26TH EORTC-NCI-AACR
2014 November
Barcelona, Spain
Poster presentation

High Correlation Between Clinical Responses to 1st Line AML Patients Treated with Cytarabine and Idarubicin and their Pharmacological Profiles in Patient Samples Measured by ExviTech